[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"author-articles-jason-morehouse":3,"author-stories-jason-morehouse":1883},[4,337,890,1332,1474],{"id":5,"title":6,"author":7,"authorBio":8,"authorJobTitle":9,"authorSlug":10,"body":11,"category":313,"description":315,"eventEndDate":316,"eventLocation":316,"eventOrganizer":316,"eventStartDate":316,"eventVenue":316,"excerpt":316,"extension":317,"featured":318,"heroBg":316,"heroBgSvg":316,"heroIllustration":316,"heroSheet":319,"heroYearbook":316,"image":320,"imageHeight":321,"imageWidth":322,"meta":323,"navigation":318,"path":324,"publishedAt":325,"seo":326,"slug":327,"status":316,"stem":328,"tags":329,"type":335,"updatedAt":325,"__hash__":336},"insights\u002Finsights\u002Fdsm-6.md","DSM-6: What the APA's Roadmap Says, and Why There's No Release Date","Jason Morehouse","Jason Morehouse is the CEO and Co-Founder of HiBoop. He built HiBoop out of personal experience navigating mental health care, and writes about measurement, diagnosis, and what better care actually looks like in practice.","CEO & Co-Founder, HiBoop","jason-morehouse",{"type":12,"value":13,"toc":302},"minimark",[14,23,35,42,45,50,53,113,120,123,132,134,138,141,144,147,149,153,156,162,168,174,176,180,183,211,214,216,220,223,229,235,243,245,249],[15,16,17,18,22],"p",{},"The short answer, because it is the thing everyone is actually searching for: ",[19,20,21],"strong",{},"there is no DSM-6 release date."," The American Psychiatric Association has not announced one. The current standard remains DSM-5-TR, published in May 2022, and it will remain the standard for years.",[15,24,25,26,29,30,34],{},"What does exist is a roadmap. The APA announced it on ",[19,27,28],{},"28 January 2026",", and the lead paper from the Structure and Dimensions Subcommittee was published in the ",[31,32,33],"em",{},"American Journal of Psychiatry"," in May 2026 (Öngür et al., 2026; PMID 41593835). The most widely cited outside estimate puts finalization \"around the year 2030\" (Kreisman, 2026). Treat that as an estimate, not a date. DSM-5 took roughly fourteen years from planning to publication.",[15,36,37,38,41],{},"So this is not news you need to act on this quarter. It is news worth reading carefully, because of ",[31,39,40],{},"what"," it proposes.",[43,44],"hr",{},[46,47,49],"h2",{"id":48},"what-the-roadmap-actually-commits-to","What the roadmap actually commits to",[15,51,52],{},"Four subcommittees are doing the work, and their titles are the clearest statement of intent available:",[54,55,56,69],"table",{},[57,58,59],"thead",{},[60,61,62,66],"tr",{},[63,64,65],"th",{},"Subcommittee",[63,67,68],{},"What it is examining",[70,71,72,83,93,103],"tbody",{},[60,73,74,80],{},[75,76,77],"td",{},[19,78,79],{},"Structure and dimensions",[75,81,82],{},"Combining categorical diagnosis with severity measured on a spectrum",[60,84,85,90],{},[75,86,87],{},[19,88,89],{},"Functionality and quality of life",[75,91,92],{},"Whether functional outcomes belong inside the diagnostic framework",[60,94,95,100],{},[75,96,97],{},[19,98,99],{},"Socioeconomic, cultural and environmental determinants",[75,101,102],{},"Broadening the factors used to reach a diagnosis",[60,104,105,110],{},[75,106,107],{},[19,108,109],{},"Biomarkers",[75,111,112],{},"Integrating objective biological measures for the first time",[15,114,115,116,119],{},"The proposed framework organizes assessment into four parts: contextual and social factors, biomarkers, severity-based diagnoses, and transdiagnostic features. And the stated ambition is to produce a ",[19,117,118],{},"living document"," — an online-centred resource that updates continuously rather than a static book every fifteen years.",[15,121,122],{},"Read that list again with a clinician's eye. Severity on a spectrum. Functional outcomes. Transdiagnostic features. Continuous revision.",[15,124,125,126,131],{},"That is a description of ",[127,128,130],"a",{"href":129},"\u002F","measurement-based care",".",[43,133],{},[46,135,137],{"id":136},"the-manual-is-catching-up-to-the-practice","The manual is catching up to the practice",[15,139,140],{},"Clinicians already doing measurement-based care have been working dimensionally for years, because the categorical model does not survive contact with a caseload. A patient does not have depression or not-depression. They have a PHQ-9 of 19 that was 24 three weeks ago, and the direction of travel matters more than the threshold they happen to sit above today.",[15,142,143],{},"Transdiagnostic features are the same story. Emotional dysregulation, sleep disruption and rumination show up across diagnostic boundaries, which is why practices end up administering measures that cut across categories rather than one per diagnosis.",[15,145,146],{},"None of this is a prediction about DSM-6. It is an observation about what the roadmap is describing: the formalization of something practice arrived at first. If the next manual grades severity and tracks function, then a single categorical judgement at intake stops being sufficient documentation. Repeated measurement becomes the substrate diagnosis sits on, rather than an optional add-on for outcome reporting.",[43,148],{},[46,150,152],{"id":151},"where-i-would-push-back","Where I would push back",[15,154,155],{},"An op-ed that only agrees is not worth writing. Three parts of this deserve skepticism.",[15,157,158,161],{},[19,159,160],{},"The biomarker ambition has been promised before."," NIMH launched the Research Domain Criteria framework in 2010 with a similar premise: move past descriptive symptom clusters toward measurable biology. Sixteen years later I am not aware of a biomarker in routine clinical use for any common mental disorder — no blood test for major depression, no imaging finding that adjudicates a bipolar diagnosis. That is an editorial judgement rather than a cited finding, and I would be glad to be corrected on it. The science may well arrive. But \"for the first time the DSM will use biology\" is a statement of intent, and intent has a poor track record here. A subcommittee cannot will a biomarker into existence.",[15,163,164,167],{},[19,165,166],{},"A living document creates problems nobody has costed."," Continuous revision is obviously better for scientific accuracy. It is genuinely hard for everything downstream. Payers adjudicate claims against fixed criteria. Medico-legal documentation is assessed against the standard in force at the time of the encounter. Training programmes, licensing exams and every piece of clinical software encode a snapshot. If criteria can change quarterly, each of those needs a versioning story, and the roadmap does not supply one. \"Which version of the criteria did you diagnose under\" is a question the field is not currently equipped to answer.",[15,169,170,173],{},[19,171,172],{},"Broadening the factors used to determine diagnosis cuts both ways."," Including socioeconomic, cultural and environmental determinants is right — context changes what a symptom means. It also widens clinical discretion, and wider discretion without tighter measurement is how you get diagnostic drift and inequity. The determinants work and the dimensions work have to ship together, or the first makes the second harder.",[43,175],{},[46,177,179],{"id":178},"when-is-dsm-6-coming-out","When is DSM-6 coming out?",[15,181,182],{},"No date has been set. What is known:",[184,185,186,193,199,205],"ul",{},[187,188,189,192],"li",{},[19,190,191],{},"DSM-5-TR (May 2022) is the current standard"," and remains the basis for diagnosis, documentation and billing.",[187,194,195,198],{},[19,196,197],{},"The roadmap was published 28 January 2026"," as a set of proposals, not as draft criteria.",[187,200,201,204],{},[19,202,203],{},"Outside estimates cluster around 2029–2030."," These are estimates from commentators, not APA commitments.",[187,206,207,210],{},[19,208,209],{},"A named successor may not even be called DSM-6."," If the manual becomes a continuously updated resource, edition numbering is part of what changes.",[15,212,213],{},"Be skeptical of any page giving you a confident release date. Several of the pages ranking for this question right now still carry dates that have already passed.",[43,215],{},[46,217,219],{"id":218},"what-this-means-for-practice-concretely","What this means for practice, concretely",[15,221,222],{},"Nothing urgent. But two things are worth deciding early, because they are cheap now and expensive later.",[15,224,225,228],{},[19,226,227],{},"Do not buy tooling that hard-codes DSM-5-TR."," If the direction of travel is dimensional severity, transdiagnostic measures and continuously revised criteria, then software with diagnostic criteria compiled into it is a liability with a known expiry date. Ask any vendor how criteria are updated, who updates them, and what happens to historical records when a definition changes.",[15,230,231,234],{},[19,232,233],{},"Start collecting longitudinal severity data now, whatever the manual says."," If DSM-6 grades severity and function, practices with three years of repeated measurement will be able to describe their patients in the new vocabulary immediately. Practices with categorical intake notes will be starting over. That is true regardless of whether the 2030 estimate holds, and it is true even if DSM-6 never ships, because the clinical value of longitudinal measurement does not depend on a manual endorsing it.",[15,236,237,238,242],{},"For the current framework, our ",[127,239,241],{"href":240},"\u002Fdsm\u002F","DSM-5-TR clinical guide"," covers the diagnostic categories, severity specifiers and the ICD crosswalk as they stand today. That is what you diagnose under now, and for some years yet.",[43,244],{},[46,246,248],{"id":247},"sources","Sources",[184,250,251,261,273,285,291],{},[187,252,253,254,260],{},"American Psychiatric Association. ",[127,255,259],{"href":256,"rel":257},"https:\u002F\u002Fwww.psychiatry.org\u002Fnews-room\u002Fnews-releases\u002Fapa-releases-roadmap-for-future-of-dsm",[258],"nofollow","APA Releases Roadmap for the Future of the DSM",". 28 January 2026.",[187,262,263,264,269,270,272],{},"Öngür D, Abi-Dargham A, Clarke DE, et al. ",[127,265,268],{"href":266,"rel":267},"https:\u002F\u002Fdoi.org\u002F10.1176\u002Fappi.ajp.20250876",[258],"The Future of DSM: A Report From the Structure and Dimensions Subcommittee",". ",[31,271,33],{},", May 2026. PMID 41593835.",[187,274,275,276,269,281,284],{},"Kreisman JJ. ",[127,277,280],{"href":278,"rel":279},"https:\u002F\u002Fwww.psychologytoday.com\u002Fus\u002Fblog\u002Fi-hate-you-dont-leave-me\u002F202602\u002Fwhat-you-can-expect-in-the-dsm-6",[258],"What You Can Expect in the DSM-6",[31,282,283],{},"Psychology Today",", 18 February 2026.",[187,286,253,287,290],{},[31,288,289],{},"Diagnostic and Statistical Manual of Mental Disorders",", Fifth Edition, Text Revision (DSM-5-TR). 2022.",[187,292,293,294,269,299,301],{},"Insel T, Cuthbert B, Garvey M, et al. ",[127,295,298],{"href":296,"rel":297},"https:\u002F\u002Fdoi.org\u002F10.1176\u002Fappi.ajp.2010.09091379",[258],"Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders",[31,300,33],{},", 2010;167(7):748-751. PMID 20595427.",{"title":303,"searchDepth":304,"depth":304,"links":305},"",3,[306,308,309,310,311,312],{"id":48,"depth":307,"text":49},2,{"id":136,"depth":307,"text":137},{"id":151,"depth":307,"text":152},{"id":178,"depth":307,"text":179},{"id":218,"depth":307,"text":219},{"id":247,"depth":307,"text":248},[314],"clinical-insights","DSM-6: what the APA's January 2026 roadmap actually commits to, why no release date exists, the four subcommittees, and what dimensional severity and a living document mean for clinical practice.",null,"md",true,false,"\u002Fimg\u002Fcontent\u002Finsights\u002Fdsm-6.webp",576,1024,{},"\u002Finsights\u002Fdsm-6","2026-09-01T09:00:00Z",{"title":6,"description":315},"dsm-6","insights\u002Fdsm-6",[327,330,331,130,332,333,334],"dsm-5-tr","diagnosis","dimensional assessment","apa","classification","post","4-jGEu1PkDuFaZ9Kr8HrJpqZ395UW8b2NXlF_VcykAA",{"id":338,"title":339,"author":7,"authorBio":8,"authorJobTitle":9,"authorSlug":10,"body":340,"category":871,"description":872,"eventEndDate":316,"eventLocation":316,"eventOrganizer":316,"eventStartDate":316,"eventVenue":316,"excerpt":316,"extension":317,"featured":319,"heroBg":316,"heroBgSvg":316,"heroIllustration":316,"heroSheet":319,"heroYearbook":316,"image":873,"imageHeight":316,"imageWidth":316,"meta":874,"navigation":318,"path":876,"publishedAt":877,"seo":878,"slug":879,"status":316,"stem":880,"tags":881,"type":335,"updatedAt":877,"__hash__":889},"insights\u002Finsights\u002Fmbc-therapy-guide.md","The Clinical Evidence for Measurement-Based Care",{"type":12,"value":341,"toc":850},[342,346,352,355,357,361,366,369,372,379,383,386,393,397,410,417,419,423,426,498,501,503,507,510,514,520,525,542,545,549,555,561,572,574,578,581,585,588,642,645,649,652,689,692,698,700,704,712,717,745,751,753,757,760,766,772,778,784,790,796,798,802,805,808,811,813,817],[46,343,345],{"id":344},"measurement-based-care-what-it-is-and-why-the-evidence-supports-it","Measurement-Based Care: What It Is and Why the Evidence Supports It",[15,347,348,351],{},[127,349,350],{"href":129},"Measurement-based care"," (MBC) is a systematic clinical approach in which validated patient-reported outcome measures are administered at each session, scored, and used to guide treatment decisions in real time. The clinician tracks response data over time rather than relying solely on clinical impression, and adjusts the course of care when the data signals a client is not progressing.",[15,353,354],{},"The phrase \"measurement-based care\" appears frequently in both clinical literature and practice guidelines, but its implementation varies widely. This guide covers the research foundation, the session-by-session workflow, which scales to use, how the billing code CPT 96127 makes it reimbursable, and practical steps for setting it up in your practice.",[43,356],{},[46,358,360],{"id":359},"the-evidence-base-for-mbc","The Evidence Base for MBC",[362,363,365],"h3",{"id":364},"lamberts-feedback-research","Lambert's Feedback Research",[15,367,368],{},"The foundational evidence for MBC comes from Michael Lambert and colleagues at Brigham Young University. Lambert's group demonstrated that therapist access to client outcome data — presented as visual feedback comparing a client's progress to expected recovery trajectories — significantly reduced treatment failure rates.",[15,370,371],{},"In a key series of studies, Lambert et al. (2003) showed that when clients were identified as \"not on track\" using standardised progress graphs, therapist feedback about this led to reliably better outcomes compared to therapists who received no such data. At-risk clients whose therapists received feedback were significantly less likely to deteriorate by treatment end.",[15,373,374,375,378],{},"Lambert, M. J., Whipple, J. L., Smart, D. W., Vermeersch, D., Nielsen, S. L., & Hawkins, E. J. (2003). Is it time for clinicians to routinely track patient outcome? A meta-analysis. ",[31,376,377],{},"Clinical Psychology: Science and Practice",", 10(3), 288–301.",[362,380,382],{"id":381},"shimokawa-et-al-2010-meta-analysis","Shimokawa et al. (2010) Meta-Analysis",[15,384,385],{},"The case for systematic outcome monitoring was strengthened by Shimokawa, Lambert, and Smart's 2010 meta-analysis, which pooled data from six randomised controlled trials involving 6,151 clients. The results showed that feedback-assisted therapy produced reliably better outcomes than treatment as usual (TAU) — particularly for the clients at highest risk of treatment failure. For clients flagged as deteriorating, therapist access to progress feedback reduced the proportion showing reliable deterioration by approximately half.",[15,387,388,389,392],{},"Shimokawa, K., Lambert, M. J., & Smart, D. W. (2010). Enhancing treatment outcome of patients at risk of treatment failure: Meta-analytic and mega-analytic review of a psychotherapy quality assurance system. ",[31,390,391],{},"Journal of Consulting and Clinical Psychology",", 78(3), 298–311.",[362,394,396],{"id":395},"miller-duncans-pcoms-research","Miller & Duncan's PCOMS Research",[15,398,399,400,404,405,409],{},"Scott D. Miller and Barry L. Duncan developed the Partners for Change Outcome Management System (PCOMS), a formal MBC framework built around two ultra-brief tools: the ",[127,401,403],{"href":402},"\u002Fassessments\u002Fors\u002F","Outcome Rating Scale (ORS)"," and the ",[127,406,408],{"href":407},"\u002Fassessments\u002Fsrs\u002F","Session Rating Scale (SRS)",". Each is a four-item visual analogue measure that takes approximately two minutes to complete and score.",[15,411,412,413,416],{},"The clinical trials supporting PCOMS found that therapists using the ORS and SRS together achieved significantly higher rates of reliable change and recovery compared to control conditions. Crucially, the improvement was not attributable to the scales themselves but to the feedback loop: therapists who reviewed scores and discussed discrepant findings with clients outperformed those who did not. Duncan, B. L., Miller, S. D., Sparks, J. A., et al. (2003). The Session Rating Scale: Preliminary psychometric properties of a \"working alliance\" measure. ",[31,414,415],{},"Journal of Brief Therapy",", 3(1), 3–12.",[43,418],{},[46,420,422],{"id":421},"mbc-vs-treatment-as-usual-outcomes-at-a-glance","MBC vs Treatment as Usual: Outcomes at a Glance",[15,424,425],{},"The research evidence consistently favours MBC over unaugmented treatment as usual across several key metrics.",[54,427,428,441],{},[57,429,430],{},[60,431,432,435,438],{},[63,433,434],{},"Outcome measure",[63,436,437],{},"Treatment as usual",[63,439,440],{},"MBC with feedback",[70,442,443,454,465,476,487],{},[60,444,445,448,451],{},[75,446,447],{},"Rate of reliable improvement",[75,449,450],{},"~50%",[75,452,453],{},"60–65%",[60,455,456,459,462],{},[75,457,458],{},"Rate of deterioration",[75,460,461],{},"5–10%",[75,463,464],{},"2–4%",[60,466,467,470,473],{},[75,468,469],{},"Average session count to reliable change",[75,471,472],{},"Varies widely",[75,474,475],{},"Reduced for flagged clients",[60,477,478,481,484],{},[75,479,480],{},"Early dropout detection",[75,482,483],{},"Low",[75,485,486],{},"High (flagged at session 3–4)",[60,488,489,492,495],{},[75,490,491],{},"Therapeutic alliance monitoring",[75,493,494],{},"None",[75,496,497],{},"Every session via SRS",[15,499,500],{},"These estimates draw from the Shimokawa et al. (2010) meta-analysis and the Lambert (2003) feedback studies. Effect sizes in MBC trials are modest (d ≈ 0.2–0.5) but consistent, and the benefit concentrates among clients who are initially not responding — the group at greatest risk of dropout and chronic treatment.",[43,502],{},[46,504,506],{"id":505},"session-by-session-implementation-the-pcoms-workflow","Session-by-Session Implementation: The PCOMS Workflow",[15,508,509],{},"The PCOMS workflow integrates two brief measures into standard session structure without meaningfully extending session length.",[362,511,513],{"id":512},"at-session-start-administer-the-ors","At session start: administer the ORS",[15,515,516,517,519],{},"Before clinical discussion begins, give the client the ",[127,518,403],{"href":402},". This is a four-item visual analogue measure of individual wellbeing, relational functioning, social\u002Fwork functioning, and overall sense of wellbeing. It takes approximately one to two minutes to complete.",[15,521,522],{},[19,523,524],{},"Score interpretation:",[184,526,527,530,536],{},[187,528,529],{},"Total scores range from 0 to 40 (higher = better functioning)",[187,531,532,535],{},[19,533,534],{},"Clinical cutoff: 25."," Scores at or below 25 indicate distress and impairment consistent with a clinical population",[187,537,538,541],{},[19,539,540],{},"Reliable Change Index (RCI): ±5 points."," A change of 5 or more points between sessions represents statistically reliable change beyond measurement error",[15,543,544],{},"Graph the ORS score over sessions. A client starting below 25 who does not show reliable improvement by session 4 is identified as \"not on track\" — the point at which the PCOMS protocol calls for direct feedback discussion and possible case consultation.",[362,546,548],{"id":547},"at-session-end-administer-the-srs","At session end: administer the SRS",[15,550,551,552,554],{},"After the clinical content of the session, give the client the ",[127,553,408],{"href":407},". This is a four-item visual analogue measure of therapeutic alliance: the relationship, goals and topics, approach and method, and overall sense of the session. It takes approximately one minute to complete.",[15,556,557,560],{},[19,558,559],{},"Why this matters:"," Research by Miller, Duncan, and colleagues consistently finds that client-rated alliance scores predict dropout and outcome, and that when clients rate alliance low and clinicians discuss this discrepancy with them, the alliance recovers and outcomes improve. Collecting the SRS without discussing discrepant scores loses most of its value.",[15,562,563,566,567,571],{},[19,564,565],{},"Clinical threshold:"," SRS scores below 36 (out of 40) warrant a brief, direct inquiry — \"I notice you rated the session a bit lower on ",[568,569,570],"span",{},"domain",". What would make this more useful for you?\" That conversation, not the number, is the intervention.",[43,573],{},[46,575,577],{"id":576},"condition-specific-scales-phq-9-and-gad-7","Condition-Specific Scales: PHQ-9 and GAD-7",[15,579,580],{},"The ORS is transdiagnostic and session-level. For condition-specific severity tracking across the course of treatment, two validated measures are the clinical standard.",[362,582,584],{"id":583},"phq-9-for-depression","PHQ-9 for depression",[15,586,587],{},"The Patient Health Questionnaire–9 (PHQ-9) is a nine-item self-report measure of depressive symptom severity over the past two weeks, scored 0–27. It maps to DSM major depression criteria and provides a validated severity tier system:",[54,589,590,600],{},[57,591,592],{},[60,593,594,597],{},[63,595,596],{},"Score",[63,598,599],{},"Severity",[70,601,602,610,618,626,634],{},[60,603,604,607],{},[75,605,606],{},"0–4",[75,608,609],{},"Minimal",[60,611,612,615],{},[75,613,614],{},"5–9",[75,616,617],{},"Mild",[60,619,620,623],{},[75,621,622],{},"10–14",[75,624,625],{},"Moderate",[60,627,628,631],{},[75,629,630],{},"15–19",[75,632,633],{},"Moderately severe",[60,635,636,639],{},[75,637,638],{},"20–27",[75,640,641],{},"Severe",[15,643,644],{},"A change of 5 or more points is generally considered clinically meaningful. The PHQ-9 is typically administered every 4 weeks in ongoing treatment, though some practices track it bi-weekly during an acute phase. It is one of the most-cited validated scales in the MBC literature and is billable under CPT 96127.",[362,646,648],{"id":647},"gad-7-for-anxiety","GAD-7 for anxiety",[15,650,651],{},"The Generalised Anxiety Disorder–7 (GAD-7) is a seven-item self-report measure of anxiety severity over the past two weeks, scored 0–21. The standard severity cutoffs are:",[54,653,654,662],{},[57,655,656],{},[60,657,658,660],{},[63,659,596],{},[63,661,599],{},[70,663,664,670,676,682],{},[60,665,666,668],{},[75,667,606],{},[75,669,609],{},[60,671,672,674],{},[75,673,614],{},[75,675,617],{},[60,677,678,680],{},[75,679,622],{},[75,681,625],{},[60,683,684,687],{},[75,685,686],{},"15–21",[75,688,641],{},[15,690,691],{},"Scores of 10 or above indicate a positive screen warranting diagnostic follow-up. Like the PHQ-9, the GAD-7 has strong psychometric support, is free to use in clinical practice, and is billable under CPT 96127.",[15,693,694,697],{},[19,695,696],{},"Practical integration:"," Administer the PHQ-9 and GAD-7 at intake and at regular intervals throughout treatment. Many MBC practices pair them with the session-level ORS: the PHQ-9 and GAD-7 track symptom severity across weeks; the ORS tracks within-session functioning at every appointment. Together they give a layered picture — broad clinical trajectory plus session-to-session responsiveness.",[43,699],{},[46,701,703],{"id":702},"billing-mbc-with-cpt-96127","Billing MBC with CPT 96127",[15,705,706,707,711],{},"Measurement-based care is not only clinically defensible — it is reimbursable. ",[127,708,710],{"href":709},"\u002Fcpt-codes\u002F96127-brief-emotional-behavioural-assessment\u002F","CPT code 96127"," covers the administration, scoring, and documentation of validated brief emotional\u002Fbehavioural assessment scales.",[15,713,714],{},[19,715,716],{},"Key billing rules:",[184,718,719,726,733,739,742],{},[187,720,721,722,725],{},"Up to ",[19,723,724],{},"4 units per encounter",", each unit representing one validated scale administered, scored, and documented",[187,727,728,729,732],{},"Bills as an ",[19,730,731],{},"add-on code"," alongside primary service codes: psychotherapy (90832\u002F90834\u002F90837), evaluation and management (99213\u002F99214), or diagnostic evaluation (90791\u002F90792)",[187,734,735,738],{},[19,736,737],{},"Documentation required per unit:"," the scale name, the resulting score, clinical interpretation (severity tier, change from prior score, treatment implication), and integration into clinical decision-making",[187,740,741],{},"Patient self-administration is acceptable; the reimbursable work is the clinician's interpretation and documentation",[187,743,744],{},"Reimbursement is approximately $4.97 per unit under the 2026 Medicare Physician Fee Schedule; commercial rates typically range $4–$6 per unit",[15,746,747,750],{},[19,748,749],{},"Example billing for a standard MBC session:","\nA 45-minute psychotherapy session (90834) in which the clinician administers the PHQ-9 and GAD-7 bills 2 units of 96127 alongside the primary code. If the ORS is also administered and documented, a third unit applies. At $5 per unit, this adds $10–$15 to the encounter — small per session, but material across a full panel.",[43,752],{},[46,754,756],{"id":755},"practical-implementation-steps","Practical Implementation Steps",[15,758,759],{},"Getting MBC established in a practice does not require a large platform investment to start. The following steps move from minimum viable implementation to a sustained routine:",[15,761,762,765],{},[19,763,764],{},"1. Choose your measures."," For a general outpatient caseload, the ORS (session-level) + PHQ-9 + GAD-7 (periodic) covers the majority of presentations. Add the SRS once comfortable with the ORS workflow.",[15,767,768,771],{},[19,769,770],{},"2. Build administration into session structure."," The ORS takes two minutes at session start. Protect this time — it works only if it happens consistently before the clinical conversation begins. The PHQ-9 and GAD-7 can be sent to clients ahead of the session as pre-visit forms.",[15,773,774,777],{},[19,775,776],{},"3. Score and graph immediately."," The feedback value of MBC depends on reviewing scores before the session ends, not logging them afterward. Software that scores and graphs each response on submission removes this friction.",[15,779,780,783],{},[19,781,782],{},"4. Discuss discrepant scores directly."," When ORS scores are not improving or SRS scores are low, raise it. Research by Miller and Duncan consistently shows that clinicians who avoid discussing unfavourable numbers lose the main benefit of the feedback loop. A simple prompt — \"Your scores have been about the same for the last few weeks. What's your sense of what's happening?\" — is usually sufficient.",[15,785,786,789],{},[19,787,788],{},"5. Document for CPT 96127."," In each session note, include: (a) scale name administered, (b) score, (c) clinical interpretation, and (d) how the score informed the session. This satisfies billing documentation requirements and creates a longitudinal clinical record.",[15,791,792,795],{},[19,793,794],{},"6. Review your data."," Aggregate score trends across your caseload identify not-on-track clients before they drop out. A review of ORS trajectories at 4-session intervals allows proactive case consultation rather than reactive response.",[43,797],{},[46,799,801],{"id":800},"summary","Summary",[15,803,804],{},"Measurement-based care — the systematic, session-level collection of patient-reported outcome data used to inform clinical decisions — is supported by a consistent evidence base spanning two decades of clinical trials and meta-analyses. The Lambert feedback studies, the Shimokawa et al. meta-analysis, and the PCOMS research by Miller and Duncan all point to the same finding: therapists who use client outcome data make better decisions and produce better results, particularly for clients who are not progressing.",[15,806,807],{},"The implementation tools are accessible. The ORS and SRS are brief, validated, and freely available for individual clinical use. The PHQ-9 and GAD-7 are the standard symptom severity measures for the most common presenting conditions. And CPT 96127 makes the administration and documentation of these scales reimbursable.",[15,809,810],{},"HiBoop does not offer the ORS or SRS. For the symptom side of this workflow, HiBoop sends measures such as the PHQ-9 and GAD-7 before sessions, scores and graphs the results, and flags clients who are not on track.",[43,812],{},[46,814,816],{"id":815},"references","References",[184,818,819,824,828,835,841],{},[187,820,821,822,416],{},"Duncan, B. L., Miller, S. D., Sparks, J. A., Claud, D. A., Reynolds, L. R., Brown, J., & Johnson, L. D. (2003). The Session Rating Scale: Preliminary psychometric properties of a \"working alliance\" measure. ",[31,823,415],{},[187,825,374,826,378],{},[31,827,377],{},[187,829,830,831,834],{},"Miller, S. D., & Duncan, B. L. (2004). ",[31,832,833],{},"The Outcome and Session Rating Scales: Administration and scoring manual",". Chicago: Institute for the Study of Therapeutic Change.",[187,836,837,838,840],{},"Miller, S. D., Duncan, B. L., Brown, J., Sparks, J. A., & Claud, D. A. (2003). The Outcome Rating Scale: A preliminary study of the reliability, validity, and feasibility of a brief visual analog measure. ",[31,839,415],{},", 2(2), 91–100.",[187,842,388,843,845,846],{},[31,844,391],{},", 78(3), 298–311. ",[127,847,848],{"href":848,"rel":849},"https:\u002F\u002Fdoi.org\u002F10.1037\u002Fa0019247",[258],{"title":303,"searchDepth":304,"depth":304,"links":851},[852,853,858,859,863,867,868,869,870],{"id":344,"depth":307,"text":345},{"id":359,"depth":307,"text":360,"children":854},[855,856,857],{"id":364,"depth":304,"text":365},{"id":381,"depth":304,"text":382},{"id":395,"depth":304,"text":396},{"id":421,"depth":307,"text":422},{"id":505,"depth":307,"text":506,"children":860},[861,862],{"id":512,"depth":304,"text":513},{"id":547,"depth":304,"text":548},{"id":576,"depth":307,"text":577,"children":864},[865,866],{"id":583,"depth":304,"text":584},{"id":647,"depth":304,"text":648},{"id":702,"depth":307,"text":703},{"id":755,"depth":307,"text":756},{"id":800,"depth":307,"text":801},{"id":815,"depth":307,"text":816},"Clinical Practice","The research behind measurement-based care: Lambert's feedback trials, the Shimokawa meta-analysis of 6,151 clients, the PCOMS workflow, and CPT 96127.","\u002Fimg\u002Fcontent\u002Finsights\u002Fmbc-therapy-guide.webp",{"published":318,"lastReviewed":875},"2026-05-26","\u002Finsights\u002Fmbc-therapy-guide","2026-05-26T09:00:00Z",{"title":339,"description":872},"mbc-therapy-guide","insights\u002Fmbc-therapy-guide",[130,882,883,884,885,886,887,888],"MBC","ORS","SRS","PCOMS","outcome monitoring","CPT 96127","feedback-informed treatment","x03DuaESEzh89XwDQGSOslVXm77Lal1RxVJ7dtvPjZQ",{"id":891,"title":892,"author":7,"authorBio":8,"authorJobTitle":9,"authorSlug":10,"body":893,"category":871,"description":1319,"eventEndDate":316,"eventLocation":316,"eventOrganizer":316,"eventStartDate":316,"eventVenue":316,"excerpt":316,"extension":317,"featured":319,"heroBg":316,"heroBgSvg":316,"heroIllustration":316,"heroSheet":319,"heroYearbook":316,"image":1320,"imageHeight":316,"imageWidth":316,"meta":1321,"navigation":318,"path":1322,"publishedAt":877,"seo":1323,"slug":1324,"status":316,"stem":1325,"tags":1326,"type":335,"updatedAt":877,"__hash__":1331},"insights\u002Finsights\u002Ftherapeutic-alliance-guide.md","Therapeutic Alliance in Mental Health: Evidence, Measurement & Outcomes",{"type":12,"value":894,"toc":1306},[895,898,901,903,907,910,930,933,935,939,946,949,956,958,962,965,969,978,981,1041,1044,1047,1050,1057,1060,1075,1078,1081,1083,1087,1090,1093,1107,1110,1113,1115,1119,1126,1140,1143,1146,1149,1151,1155,1160,1163,1189,1192,1194,1198,1201,1204,1206,1208],[15,896,897],{},"Therapeutic alliance is one of the most replicated predictors of psychotherapy outcome in the research literature. Across treatment modalities, client populations, and clinical settings, the quality of the relationship between client and therapist consistently accounts for a meaningful portion of variance in outcomes — more, in many studies, than the specific techniques or protocols being used.",[15,899,900],{},"That isn't an argument against technique. It's an argument for taking the relationship seriously as a clinical variable, one that can be monitored and actively managed rather than left to intuition.",[43,902],{},[46,904,906],{"id":905},"what-is-the-therapeutic-alliance","What is the therapeutic alliance?",[15,908,909],{},"The dominant conceptual framework comes from Edward Bordin's 1979 tripartite model. Bordin proposed that the working alliance — the collaborative dimension of the therapeutic relationship — consists of three interrelated components:",[184,911,912,918,924],{},[187,913,914,917],{},[19,915,916],{},"Bond:"," The quality of the personal connection between client and therapist. This includes mutual trust, acceptance, and the sense of being genuinely understood.",[187,919,920,923],{},[19,921,922],{},"Goals:"," Shared agreement on the outcomes the client and therapist are working toward. Alliance is weakened when client and therapist hold different ideas of what treatment is for.",[187,925,926,929],{},[19,927,928],{},"Tasks:"," Agreement on the therapeutic activities and methods being used. Clients need to experience the work as relevant and credible — not just endure it.",[15,931,932],{},"Bordin argued that the alliance was not specific to any one therapeutic model. It was a pan-theoretical construct, present in every effective therapy regardless of orientation. That framing held up well under subsequent empirical scrutiny.",[43,934],{},[46,936,938],{"id":937},"why-it-matters-the-evidence-base","Why it matters: the evidence base",[15,940,941,942,945],{},"Bruce Wampold's 2001 contextual model of psychotherapy — articulated in ",[31,943,944],{},"The Great Psychotherapy Debate"," — drew on meta-analytic data to argue that so-called \"common factors\" (including the alliance, empathy, and client expectations) account for substantially more outcome variance than specific treatment techniques. In his analysis, specific ingredients accounted for roughly 1% of variance; common factors, including alliance, accounted for considerably more.",[15,947,948],{},"The most comprehensive recent synthesis is Wampold and Flückiger's 2023 World Psychiatry meta-analysis (doi: 10.1002\u002Fwps.21035), which reviewed the alliance-outcome literature and confirmed the relationship as one of the most consistently supported in clinical psychology. Across 17 meta-analyses, the alliance-outcome correlation was consistently significant, with effect sizes in the moderate range. Critically, the authors noted that the alliance is both a predictor and a product of good treatment — early alliance formation matters, but so does the ability to repair it when ruptures occur.",[15,950,951,952,955],{},"Flückiger and colleagues' 2018 meta-analysis in ",[31,953,954],{},"Psychotherapy"," (covering 295 studies, n = 30,000+) found an average weighted correlation of r = .278 between alliance and outcome. This makes the alliance one of the most replicated findings in psychotherapy research, cutting across cognitive-behavioural, psychodynamic, humanistic, and integrative approaches.",[43,957],{},[46,959,961],{"id":960},"how-to-measure-therapeutic-alliance","How to measure therapeutic alliance",[15,963,964],{},"There are two main scales in routine clinical use, suited to different purposes.",[362,966,968],{"id":967},"working-alliance-inventory-wai","Working Alliance Inventory (WAI)",[15,970,971,972,977],{},"The ",[19,973,974],{},[127,975,968],{"href":976},"\u002Fassessments\u002Fwai\u002F"," was developed by Adam Horvath and Leslie Greenberg (1989) directly from Bordin's tripartite model. It operationalises the Bond, Goal, and Task components in three parallel subscales.",[15,979,980],{},"Three versions exist:",[54,982,983,999],{},[57,984,985],{},[60,986,987,990,993,996],{},[63,988,989],{},"Version",[63,991,992],{},"Items",[63,994,995],{},"Administration time",[63,997,998],{},"Best use",[70,1000,1001,1015,1029],{},[60,1002,1003,1006,1009,1012],{},[75,1004,1005],{},"WAI (original)",[75,1007,1008],{},"36",[75,1010,1011],{},"10–15 min",[75,1013,1014],{},"Clinical trials, training supervision",[60,1016,1017,1020,1023,1026],{},[75,1018,1019],{},"WAI-S (short form)",[75,1021,1022],{},"12",[75,1024,1025],{},"3–5 min",[75,1027,1028],{},"Periodic research assessment",[60,1030,1031,1034,1036,1038],{},[75,1032,1033],{},"WAI-SR (revised short form)",[75,1035,1022],{},[75,1037,1025],{},[75,1039,1040],{},"Outpatient and online settings",[15,1042,1043],{},"The WAI-SR (Munder et al., 2010) is one of the most widely used versions in clinical research settings. It maintains strong psychometric properties and is well-validated in both outpatient and online intervention contexts.",[15,1045,1046],{},"Typical administration timing: after sessions 3 and 8, or at fixed intervals across a treatment episode. The WAI is not designed for every-session use — it is better suited to periodic structured assessment of alliance quality.",[362,1048,408],{"id":1049},"session-rating-scale-srs",[15,1051,971,1052,1056],{},[19,1053,1054],{},[127,1055,408],{"href":407}," takes a different approach. Developed by Barry Duncan and Scott Miller (2003), it is an ultra-brief 4-item measure designed to be administered at the end of every session, in under one minute.",[15,1058,1059],{},"Each item is a 10-centimetre visual analog scale covering:",[1061,1062,1063,1066,1069,1072],"ol",{},[187,1064,1065],{},"Relationship (feeling heard, understood, and respected)",[187,1067,1068],{},"Goals and Topics (addressing what matters to the client)",[187,1070,1071],{},"Approach or Method (fit of the therapist's approach)",[187,1073,1074],{},"Overall (general sense of the session)",[15,1076,1077],{},"Total scores range from 0–40. A score at or below 36 is the clinical cutoff for a meaningful alliance concern — a signal to open a conversation about the client's experience before the session closes.",[15,1079,1080],{},"The SRS is part of the Partners for Change Outcome Management System (PCOMS), a feedback-informed treatment framework. Research by Duncan (2012) shows that practitioners who routinely collect and respond to SRS feedback demonstrate significantly better client outcomes than those who rely on clinical intuition alone.",[43,1082],{},[46,1084,1086],{"id":1085},"real-time-alliance-monitoring-in-practice","Real-time alliance monitoring in practice",[15,1088,1089],{},"The clinical case for session-by-session alliance monitoring rests on a straightforward problem: practitioners are poor at detecting when clients are dissatisfied. A 2005 study by Hannan et al. found that therapists predicted which clients would deteriorate at only slightly above chance. The clients' own ratings, collected with brief tools like the SRS, were better predictors.",[15,1091,1092],{},"Feedback-informed treatment (FIT) operationalises this insight. The core practice is simple:",[1061,1094,1095,1098,1101,1104],{},[187,1096,1097],{},"Administer the SRS at the end of each session.",[187,1099,1100],{},"Score it before the client leaves.",[187,1102,1103],{},"Discuss any items that scored noticeably low — not defensively, but with genuine curiosity.",[187,1105,1106],{},"Adjust approach based on what you learn.",[15,1108,1109],{},"This loop — measure, review, discuss, adjust — converts the alliance from background noise into a clinical variable. Low SRS scores that are acknowledged and addressed are associated with better outcomes than low scores that go unnoticed or unaddressed (Duncan, 2012).",[15,1111,1112],{},"For practitioners in training or supervision, combining the SRS (session-by-session) with the WAI (periodic structured assessment) provides both real-time feedback and a more granular picture of the Bond\u002FGoal\u002FTask components across the arc of treatment.",[43,1114],{},[46,1116,1118],{"id":1117},"when-the-alliance-ruptures","When the alliance ruptures",[15,1120,1121,1122,1125],{},"Even in effective treatments, the alliance does not remain stable. Ruptures — moments of tension, misalignment, or breakdown in the therapeutic relationship — are common. Safran and Muran's rupture-repair model, developed through the late 1990s and formalised in their 2000 book ",[31,1123,1124],{},"Negotiating the Therapeutic Alliance",", describes two types:",[184,1127,1128,1134],{},[187,1129,1130,1133],{},[19,1131,1132],{},"Withdrawal ruptures:"," The client disengages — becomes compliant but distant, avoids discussing something important, or reduces emotional engagement.",[187,1135,1136,1139],{},[19,1137,1138],{},"Confrontation ruptures:"," The client expresses dissatisfaction, frustration, or criticism of the therapist or treatment.",[15,1141,1142],{},"Confrontation ruptures are often easier to detect. Withdrawal ruptures can persist for sessions before becoming visible, which is part of why routine measurement matters — a sustained drop in SRS scores without obvious explanation is often a withdrawal rupture in progress.",[15,1144,1145],{},"The repair process involves three steps: noticing the rupture, marking it explicitly (rather than working around it), and exploring the client's experience with genuine openness. Safran and Muran's Alliance-Focused Therapy and subsequent research have demonstrated that successful repairs are associated with better outcomes, and in some cases with stronger alliances post-repair than pre-rupture.",[15,1147,1148],{},"Practitioners who avoid ruptures by adjusting their approach before the client disengages show different patterns from those who allow ruptures to develop unaddressed. Real-time monitoring makes early course correction possible.",[43,1150],{},[46,1152,1154],{"id":1153},"integrating-alliance-measurement-into-clinical-workflows","Integrating alliance measurement into clinical workflows",[15,1156,1157,1159],{},[127,1158,350],{"href":129}," frameworks that include alliance monitoring have a practical advantage over those that track symptoms alone: they capture a dimension of treatment quality that symptom scales cannot. A client's PHQ-9 scores may be stable while their alliance is deteriorating — an early indicator that treatment is drifting before the symptom picture moves.",[15,1161,1162],{},"Practical integration points:",[184,1164,1165,1171,1177,1183],{},[187,1166,1167,1170],{},[19,1168,1169],{},"Session-end:"," Administer the SRS every session. Score it before the client leaves.",[187,1172,1173,1176],{},[19,1174,1175],{},"Mid-treatment review:"," Administer the WAI-SR at sessions 3–4 and again at session 8–10 to get subscale-level data on where Bond, Goal, or Task alignment is weakest.",[187,1178,1179,1182],{},[19,1180,1181],{},"Case formulation:"," Use WAI subscale profiles to guide supervision — a low Task score suggests the client finds the approach irrelevant; a low Goal score suggests the treatment target needs renegotiation.",[187,1184,1185,1188],{},[19,1186,1187],{},"Rupture detection:"," A sustained SRS score at or below 36, or a pattern of declining scores, warrants direct metacommunication before the alliance deteriorates further.",[15,1190,1191],{},"HiBoop does not currently offer the SRS or WAI. It supports session-by-session symptom tracking with measures such as the PHQ-9 and GAD-7, which practitioners can review alongside the alliance measure they already use.",[43,1193],{},[46,1195,1197],{"id":1196},"the-bottom-line","The bottom line",[15,1199,1200],{},"Therapeutic alliance is not soft-skills territory. It is a measurable clinical variable with a well-documented evidence base, standardised scales, and a clear relationship to treatment outcomes. Practitioners who monitor it — using tools like the SRS at every session and the WAI at regular intervals — can detect early signals of misalignment, repair ruptures before they compound, and make more informed decisions about when and how to adjust their approach.",[15,1202,1203],{},"The Wampold and Flückiger 2023 meta-analysis is unambiguous: the alliance is among the most reliable predictors of psychotherapy outcome, and it responds to deliberate clinical attention. Measurement is how that attention becomes systematic.",[43,1205],{},[46,1207,816],{"id":815},[184,1209,1210,1221,1232,1238,1248,1259,1270,1281,1288,1295],{},[187,1211,1212,1213,1216,1217],{},"Bordin, E. S. (1979). The generalizability of the psychoanalytic concept of the working alliance. ",[31,1214,1215],{},"Psychotherapy: Theory, Research & Practice",", 16(3), 252–260. ",[127,1218,1219],{"href":1219,"rel":1220},"https:\u002F\u002Fdoi.org\u002F10.1037\u002Fh0085885",[258],[187,1222,1223,1224,1227,1228],{},"Duncan, B. L. (2012). The partners for change outcome management system (PCOMS): The heart and soul of change project. ",[31,1225,1226],{},"Canadian Psychology",", 53(2), 93–104. ",[127,1229,1230],{"href":1230,"rel":1231},"https:\u002F\u002Fdoi.org\u002F10.1037\u002Fa0027762",[258],[187,1233,1234,1235,1237],{},"Duncan, B. L., Miller, S. D., Sparks, J. A., Claud, D. A., Reynolds, L. R., Brown, J., & Johnson, L. D. (2003). The session rating scale: Preliminary psychometric properties of a \"working\" alliance measure. ",[31,1236,415],{},", 2(1), 3–12.",[187,1239,1240,1241,1243,1244],{},"Flückiger, C., Del Re, A. C., Wampold, B. E., & Horvath, A. O. (2018). The alliance in adult psychotherapy: A meta-analytic synthesis. ",[31,1242,954],{},", 55(4), 316–340. ",[127,1245,1246],{"href":1246,"rel":1247},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29792475\u002F",[258],[187,1249,1250,1251,1254,1255],{},"Hannan, C., Lambert, M. J., Harmon, C., Nielsen, S. L., Smart, D. W., Shimokawa, K., & Sutton, S. W. (2005). A lab test and algorithms for identifying clients at risk for treatment failure. ",[31,1252,1253],{},"Journal of Clinical Psychology",", 61(2), 155–163. ",[127,1256,1257],{"href":1257,"rel":1258},"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fjclp.20108",[258],[187,1260,1261,1262,1265,1266],{},"Horvath, A. O., & Greenberg, L. S. (1989). Development and validation of the Working Alliance Inventory. ",[31,1263,1264],{},"Journal of Counselling Psychology",", 36(2), 223–233. ",[127,1267,1268],{"href":1268,"rel":1269},"https:\u002F\u002Fdoi.org\u002F10.1037\u002F0022-0167.36.2.223",[258],[187,1271,1272,1273,1276,1277],{},"Munder, T., Wilmers, F., Leonhart, R., Linster, H. W., & Barth, J. (2010). Working Alliance Inventory-Short Revised (WAI-SR): Psychometric properties in outpatients and inpatients. ",[31,1274,1275],{},"Clinical Psychology & Psychotherapy",", 17(3), 231–239. ",[127,1278,1279],{"href":1279,"rel":1280},"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fcpp.658",[258],[187,1282,1283,1284,1287],{},"Safran, J. D., & Muran, J. C. (2000). ",[31,1285,1286],{},"Negotiating the Therapeutic Alliance: A Relational Treatment Guide",". Guilford Press.",[187,1289,1290,1291,1294],{},"Wampold, B. E. (2001). ",[31,1292,1293],{},"The Great Psychotherapy Debate: Models, Methods, and Findings",". Lawrence Erlbaum.",[187,1296,1297,1298,1301,1302],{},"Wampold, B. E., & Flückiger, C. (2023). The alliance in mental health care: conceptualization, evidence and clinical applications. ",[31,1299,1300],{},"World Psychiatry",", 22(1), 25–41. ",[127,1303,1304],{"href":1304,"rel":1305},"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fwps.21035",[258],{"title":303,"searchDepth":304,"depth":304,"links":1307},[1308,1309,1310,1314,1315,1316,1317,1318],{"id":905,"depth":307,"text":906},{"id":937,"depth":307,"text":938},{"id":960,"depth":307,"text":961,"children":1311},[1312,1313],{"id":967,"depth":304,"text":968},{"id":1049,"depth":304,"text":408},{"id":1085,"depth":307,"text":1086},{"id":1117,"depth":307,"text":1118},{"id":1153,"depth":307,"text":1154},{"id":1196,"depth":307,"text":1197},{"id":815,"depth":307,"text":816},"What is therapeutic alliance, why it predicts outcomes, and how to measure it with WAI and SRS in routine clinical practice.","\u002Fimg\u002Fcontent\u002Finsights\u002Ftherapeutic-alliance-guide.webp",{"lastReviewed":875,"published":318},"\u002Finsights\u002Ftherapeutic-alliance-guide",{"title":892,"description":1319},"therapeutic-alliance-guide","insights\u002Ftherapeutic-alliance-guide",[1327,130,1328,1329,884,1330,888],"therapeutic alliance","working alliance","WAI","outcomes","rmayhb4yY2EaeGF0DplLCE4oKfOKYv6GBSipSkgaLOU",{"id":1333,"title":1334,"author":7,"authorBio":1335,"authorJobTitle":9,"authorSlug":10,"body":1336,"category":1453,"description":1340,"eventEndDate":316,"eventLocation":316,"eventOrganizer":316,"eventStartDate":316,"eventVenue":316,"excerpt":316,"extension":317,"featured":318,"heroBg":316,"heroBgSvg":316,"heroIllustration":1455,"heroSheet":319,"heroYearbook":316,"image":1456,"imageHeight":1457,"imageWidth":1458,"meta":1459,"navigation":318,"path":1460,"publishedAt":1461,"seo":1462,"slug":1463,"status":316,"stem":1464,"tags":1465,"type":335,"updatedAt":1472,"__hash__":1473},"insights\u002Finsights\u002Fclinical-access.md","Clinical tools should not cost more for the clinicians who have the least","Jason Morehouse is CEO and Co-Founder of HiBoop, a measurement-based care platform built for clinical practices of all sizes.",{"type":12,"value":1337,"toc":1446},[1338,1341,1344,1350,1354,1357,1360,1363,1369,1372,1376,1379,1382,1385,1396,1399,1403,1406,1409,1412,1416,1419,1422,1425,1429,1432,1435,1437,1440],[15,1339,1340],{},"The PHQ-9 is in the public domain. The GAD-7 is the same. The PCL-5, the C-SSRS: most of the validated scales clinicians use every day were developed with public funding, validated through peer-reviewed research, and released without charge so that any provider, anywhere, could use them.",[15,1342,1343],{},"The research is free. The infrastructure to use it properly is not.",[15,1345,1346,1347,1349],{},"That gap is where clinical ",[127,1348,130],{"href":129}," tools have historically lived, leaving solo therapists in community practices, psychologists running one-person clinics, and counsellors in rural settings without a realistic path to structured outcomes measurement.",[46,1351,1353],{"id":1352},"the-inequality-hiding-in-plain-sight","The inequality hiding in plain sight",[15,1355,1356],{},"A mid-size group practice paying $200 a month for unlimited providers and a full assessment library is paying roughly $10–20 per clinician seat. That's reasonable. That works.",[15,1358,1359],{},"A solo provider paying the same $200 a month (or more, in tiered systems) is paying the full freight for a platform designed to justify its price across a team. The math never works out.",[15,1361,1362],{},"The result: the providers with the narrowest operating margins, often serving the communities with the greatest need, either skip structured outcomes measurement entirely or rely on paper and manual scoring. Both have costs. Paper adds scoring errors. Skipping MBC means missing the clinical signal that a patient is not improving, or is deteriorating.",[1364,1365,1366],"blockquote",{},[15,1367,1368],{},"Patients whose clinicians receive regular feedback on progress are significantly less likely to deteriorate or drop out. Lambert, Whipple & Kleinstäuber (2018) found that routine outcome monitoring nearly doubled clinically significant recovery rates in patients at risk of poor outcomes.",[15,1370,1371],{},"Solo providers know this. They want to measure. They don't want to pay a team-scale fee for a one-person practice.",[46,1373,1375],{"id":1374},"what-we-built-and-why","What we built, and why",[15,1377,1378],{},"Care is HiBoop's plan for one clinician: $25 a month, month to month, no credit card to start. Core validated scales including the PHQ-9, GAD-7, PCL-5, and C-SSRS, scoring on submission, and individual patient outcome tracking. Export your data anytime. No lock-in.",[15,1380,1381],{},"The price is set for a one-person practice, not divided down from a team plan. Access to clinical measurement tools should not depend on the size of your practice.",[15,1383,1384],{},"If you are a clinician working one-on-one with patients, you should be able to:",[184,1386,1387,1390,1393],{},[187,1388,1389],{},"Send a PHQ-9 digitally before a session and have it scored before the patient walks through the door",[187,1391,1392],{},"Track a patient's GAD-7 trend over six months without building a spreadsheet",[187,1394,1395],{},"Receive a safety flag when a patient's C-SSRS scores cross a clinical threshold, the moment they submit",[15,1397,1398],{},"These are not advanced features. They are the floor of what measurement-based care means. Solo providers should have them.",[46,1400,1402],{"id":1401},"what-this-isnt","What this isn't",[15,1404,1405],{},"Care is not a trial. It does not expire. It is also not the full HiBoop platform.",[15,1407,1408],{},"Care has one clinician seat. It uses the core scales, not the full library available on Team. It has per-patient progress charts, not practice-wide caseload visibility.",[15,1410,1411],{},"When a practice grows to a second clinician, a third, a group, the economics shift. Team, from $200 a month with unlimited clinicians, the full library, and practice-wide outcomes visibility, becomes the right fit. That move should happen because the practice is growing, not because Care was never sustainable for one clinician.",[46,1413,1415],{"id":1414},"who-care-is-for","Who Care is for",[15,1417,1418],{},"Solo providers working in independent practice. Psychologists in private settings. Counsellors running their own clinic. Registered Social Workers doing one-on-one sessions. Nurse practitioners in community health. Clinicians who do not work within a larger organization and are figuring out outcomes measurement on their own.",[15,1420,1421],{},"It is also for clinical training programs (graduate students, practicum placements, supervised clinical work) where structured measurement matters and budget is real.",[15,1423,1424],{},"And it is for clinicians who are considering HiBoop for a larger practice but want to evaluate it properly with their own patients before bringing it to a team. Care lets you do that month to month, with no time box.",[46,1426,1428],{"id":1427},"the-principle-underneath-it","The principle underneath it",[15,1430,1431],{},"We are a company that builds tools for the people providing care. Those tools should serve the clinician, and through the clinician, the patient. Whether that clinician works in a 20-seat group practice or alone in a rented room in a community health building, the clinical obligation is the same.",[15,1433,1434],{},"Access to the infrastructure for good measurement should reflect that.",[43,1436],{},[15,1438,1439],{},"The scales are public. The infrastructure should be within reach of the clinician working alone, too. Care is $25 a month, one clinician, no credit card to start, and you can send your first check-in today.",[15,1441,1442],{},[127,1443,1445],{"href":1444},"\u002Fstart\u002F","Get started",{"title":303,"searchDepth":304,"depth":304,"links":1447},[1448,1449,1450,1451,1452],{"id":1352,"depth":307,"text":1353},{"id":1374,"depth":307,"text":1375},{"id":1401,"depth":307,"text":1402},{"id":1414,"depth":307,"text":1415},{"id":1427,"depth":307,"text":1428},[314,1454],"product","\u002Fimg\u002Fcontent\u002Finsights\u002Fclinical-access-hero.svg","\u002Fimg\u002Fcontent\u002Finsights\u002Fscience-behind.webp",630,1200,{},"\u002Finsights\u002Fclinical-access","2026-05-13T09:00:00Z",{"title":1334,"description":1340},"clinical-access","insights\u002Fclinical-access",[1466,1467,1468,1469,1470,1471],"practice-plan","measurement-based-care","access","solo-provider","clinical-tools","mbc","2026-10-10T09:00:00Z","bthfc-f_H0pkkb9DsKuDXHSmfft3neAixeOHELnFroY",{"id":1475,"title":1476,"author":7,"authorBio":8,"authorJobTitle":9,"authorSlug":10,"body":1477,"category":1866,"description":1481,"eventEndDate":316,"eventLocation":316,"eventOrganizer":316,"eventStartDate":316,"eventVenue":316,"excerpt":316,"extension":317,"featured":318,"heroBg":316,"heroBgSvg":316,"heroIllustration":316,"heroSheet":319,"heroYearbook":316,"image":1867,"imageHeight":316,"imageWidth":316,"meta":1868,"navigation":318,"path":1869,"publishedAt":1870,"seo":1871,"slug":1872,"status":316,"stem":1873,"tags":1874,"type":335,"updatedAt":1870,"__hash__":1882},"insights\u002Finsights\u002Fadhd-vs-autism.md","AuDHD: What Happens When ADHD and Autism Coexist",{"type":12,"value":1478,"toc":1856},[1479,1482,1489,1496,1498,1502,1505,1508,1514,1520,1523,1616,1619,1621,1625,1628,1631,1634,1637,1639,1643,1646,1649,1652,1655,1657,1661,1664,1667,1670,1673,1675,1679,1682,1695,1707,1710,1712,1716,1719,1742,1745,1747,1749,1752,1755,1757,1759],[15,1480,1481],{},"For decades, clinicians were told ADHD and autism couldn't coexist. The DSM-IV made them mutually exclusive. If you had one, you couldn't officially have the other.",[15,1483,1484,1485,1488],{},"DSM-5 dropped that rule in 2013. The research since then has been unambiguous: ADHD and autism co-occur constantly. A 2023 meta-analysis covering 590,000 participants found ADHD among the most frequently co-occurring conditions in autism spectrum disorder (Micai et al., 2023). Roughly ",[19,1486,1487],{},"50–70% of autistic people meet full criteria for ADHD"," (Leitner, 2014).",[15,1490,1491,1492,1495],{},"That combination has a name in the neurodivergent community: ",[19,1493,1494],{},"AuDHD",". And it's not a rare edge case. It's a common presentation that clinical training has historically been poorly equipped to recognize.",[43,1497],{},[46,1499,1501],{"id":1500},"why-each-condition-makes-the-other-harder-to-see","Why each condition makes the other harder to see",[15,1503,1504],{},"ADHD and autism share enough surface features that it's easy to see one and stop looking. Both can present as inattention, social difficulty, emotional dysregulation, and sensory sensitivity. In a busy intake, they look nearly identical.",[15,1506,1507],{},"But their underlying mechanisms are different, and that matters for how they interact.",[15,1509,1510,1513],{},[19,1511,1512],{},"ADHD"," is a problem of attentional regulation and executive function. The brain struggles to filter, prioritize, and sustain directed effort toward low-interest tasks. Hyperfocus is real; the issue is that attention is demand-driven rather than intention-driven.",[15,1515,1516,1519],{},[19,1517,1518],{},"Autism"," is a difference in social communication and sensory processing. The brain processes social information differently and often has a stronger need for predictability. Sensory sensitivities that are present-but-not-diagnostic in ADHD are diagnostically central in autism.",[15,1521,1522],{},"Here's where the presentations converge, and why each can mask the other:",[54,1524,1525,1536],{},[57,1526,1527],{},[60,1528,1529,1532,1534],{},[63,1530,1531],{},"Symptom area",[63,1533,1512],{},[63,1535,1518],{},[70,1537,1538,1551,1564,1577,1590,1603],{},[60,1539,1540,1545,1548],{},[75,1541,1542],{},[19,1543,1544],{},"Attention",[75,1546,1547],{},"Distracted; difficulty sustaining focus on low-interest tasks",[75,1549,1550],{},"Intense narrow focus on preferred interests; overwhelmed by non-preferred input",[60,1552,1553,1558,1561],{},[75,1554,1555],{},[19,1556,1557],{},"Social difficulty",[75,1559,1560],{},"Downstream of inattention and impulsivity; knows the rules, struggles to follow them",[75,1562,1563],{},"Upstream; the implicit social rules aren't intuitively accessible in the same way",[60,1565,1566,1571,1574],{},[75,1567,1568],{},[19,1569,1570],{},"Emotional dysregulation",[75,1572,1573],{},"Fast, intense reactions; frustration intolerance",[75,1575,1576],{},"Meltdowns driven by sensory overload or disrupted routine; alexithymia",[60,1578,1579,1584,1587],{},[75,1580,1581],{},[19,1582,1583],{},"Sensory sensitivities",[75,1585,1586],{},"Present but not diagnostic",[75,1588,1589],{},"Core feature; DSM-5-TR includes them in the restricted\u002Frepetitive behavior criteria",[60,1591,1592,1597,1600],{},[75,1593,1594],{},[19,1595,1596],{},"Executive function",[75,1598,1599],{},"Initiation, working memory, task-switching",[75,1601,1602],{},"Planning, cognitive flexibility, strong preference for routine and predictability",[60,1604,1605,1610,1613],{},[75,1606,1607],{},[19,1608,1609],{},"Repetitive behavior",[75,1611,1612],{},"Fidgeting, restlessness, impulsive movement",[75,1614,1615],{},"Stimming, rigid routines, deeply specific special interests",[15,1617,1618],{},"In a clinical intake, a person with either condition, or both, might describe the same things: difficulty at work, exhaustion from social situations, feeling like they have to work twice as hard as everyone else. The symptoms sound the same. The cause, and the combination, is different.",[43,1620],{},[46,1622,1624],{"id":1623},"what-audhd-actually-looks-like","What AuDHD actually looks like",[15,1626,1627],{},"When both are present, you don't just add the traits. They interact in ways that don't look like either condition's textbook presentation.",[15,1629,1630],{},"ADHD pulls toward novelty. Autism pulls toward routine and predictability. In the same person, this creates a kind of internal friction: a drive to seek new stimulation that crashes against an equally strong need for structure. The cognitive load is high. The exhaustion is real.",[15,1632,1633],{},"Sensory overwhelm, central to autism, can trigger ADHD-like dysregulation. Not because attention is broken, but because the nervous system is overloaded and executive function degrades under that load. The 2020 Young et al. expert consensus paper describes it clearly: each condition modifies how the other presents, which means standard diagnostic scales may underperform when used in isolation.",[15,1635,1636],{},"In adults, the picture is further complicated by years of adaptation. By the time someone is sitting in front of a clinician, they've usually built systems, memorized scripts, masked the parts that don't fit. What shows up in the room looks like anxiety, burnout, or treatment-resistant depression, not a neurodevelopmental profile. A lot of adults with AuDHD get one diagnosis at best, or none at all.",[43,1638],{},[46,1640,1642],{"id":1641},"why-women-get-missed","Why women get missed",[15,1644,1645],{},"A 2024 qualitative study by Craddock looked specifically at women's experiences of late AuDHD diagnosis. The findings were damning.",[15,1647,1648],{},"Gender norms led clinicians to interpret autistic and ADHD traits in women as anxiety, emotional dysregulation, or personality disorder. Masking was more intensive and more sustained. The cost showed up as burnout, exhaustion, and identity confusion.",[15,1650,1651],{},"Many women reached diagnosis only because something broke: a relationship ending, a job loss, a health crisis. For several, perimenopause was the catalyst. Hormonal changes appear to reduce the capacity to mask, making traits visible that had been suppressed for decades. That's often when women finally get a referral that leads somewhere.",[15,1653,1654],{},"Craddock uses the phrase \"epistemic injustice\": the idea that these women's accounts of their own experience were systematically disbelieved or reframed. It's what happens when screening tools and clinical training are built around a single demographic.",[43,1656],{},[46,1658,1660],{"id":1659},"medication-is-more-complicated-in-audhd","Medication is more complicated in AuDHD",[15,1662,1663],{},"ADHD in AuDHD isn't just harder to diagnose. It's harder to treat.",[15,1665,1666],{},"A 2020 Swedish registry study by Johansson et al. followed 34,374 people with pure ADHD and 5,012 with co-occurring ADHD and autism. The ADHD+ASD group was less likely to start continuous medication treatment (76.2% vs 80.5%) and more likely to be prescribed second-line agents rather than first-line methylphenidate. When methylphenidate was prescribed, it was at lower doses.",[15,1668,1669],{},"This suggests the autistic nervous system responds differently to stimulant medication: sensory load, baseline anxiety, and the way arousal states interact with attention regulation all change the picture. AuDHD is not a variation of ADHD that responds identically to the same protocol.",[15,1671,1672],{},"The practical implication: if you're not tracking outcomes longitudinally in AuDHD patients, you're working without the information you need. A dose that works for a pure-ADHD patient may do nothing, or worsen things, for someone with both.",[43,1674],{},[46,1676,1678],{"id":1677},"screen-for-both-independently","Screen for both, independently",[15,1680,1681],{},"Because these conditions overlap so much, assessment should evaluate them independently, not use one to rule out the other. Shulman et al. reviewed diagnostic scales in dual diagnosis and found no single scale reliably captures the interaction. Assessment needs to be multi-modal.",[15,1683,1684,1687,1688,1694],{},[19,1685,1686],{},"For autism:"," The ",[19,1689,1690],{},[127,1691,1693],{"href":1692},"\u002Fassessments\u002Fraads-r\u002F","RAADS-R (Ritvo Autism Asperger Diagnostic Scale–Revised)"," is an 80-item validated self-report tool designed specifically for adults. It demonstrates 97% sensitivity and 100% specificity (Ritvo et al., 2011) and asks about traits across the lifespan, not just current behavior, which makes it particularly useful for high-masking presentations.",[15,1696,1697,1687,1700,1706],{},[19,1698,1699],{},"For ADHD:",[19,1701,1702],{},[127,1703,1705],{"href":1704},"\u002Fassessments\u002Fasrs\u002F","ASRS-v1.1 (World Health Organization Adult ADHD Self-Report Scale)"," is an 18-item validated scale developed with the World Health Organization. Its 6-item screener has 99% specificity for adult ADHD (Kessler et al., 2005).",[15,1708,1709],{},"Elevated scores on both aren't noise. They're information. Neither result cancels the other. Score both, and read them side by side.",[43,1711],{},[46,1713,1715],{"id":1714},"what-changes-with-an-accurate-picture","What changes with an accurate picture",[15,1717,1718],{},"Getting this right has real downstream effects:",[184,1720,1721,1727,1733,1739],{},[187,1722,1723,1726],{},[19,1724,1725],{},"Stimulant medications"," are first-line for ADHD and often effective in AuDHD, but autistic individuals are more sensitive to side effects on average, so dosing warrants closer monitoring",[187,1728,1729,1732],{},[19,1730,1731],{},"Behavioural strategies"," differ: ADHD management builds external structure; autism support involves sensory accommodation and reducing unpredictability",[187,1734,1735,1738],{},[19,1736,1737],{},"Therapy"," needs adapting: CBT for ADHD focuses on executive function; for autism, it often centers on emotional recognition, managing camouflaging fatigue, and self-advocacy",[187,1740,1741],{},"An unrecognized autism diagnosis in someone treated only for ADHD often results in persistent social difficulties, burnout, and the appearance of a treatment-resistant presentation, when the real issue is an incomplete clinical picture",[15,1743,1744],{},"AuDHD patients also frequently present with co-occurring anxiety, depression, and sleep disorders. Each one changes the clinical picture. Treating anxiety without recognizing the autistic sensory sensitivity driving it produces partial results. Treating depression without recognizing the ADHD executive dysfunction contributing to hopelessness misses part of the cause. When the picture is this layered, a single intake doesn't give you enough. Longitudinal measurement across multiple domains does.",[43,1746],{},[46,1748,1197],{"id":1196},[15,1750,1751],{},"AuDHD isn't a diagnostic error to be resolved. It's a real, common presentation. The question isn't always which one. Often it's which combination, how they interact, and what that means for treatment.",[15,1753,1754],{},"Running validated screens for both conditions (the RAADS-R and ASRS alongside each other) gives you the full picture without guessing. That's not more work. It's more accurate work.",[43,1756],{},[46,1758,816],{"id":815},[184,1760,1761,1767,1774,1785,1796,1803,1810,1817,1828,1835,1842,1849],{},[187,1762,1763,1764,1766],{},"American Psychiatric Association. (2022). ",[31,1765,289],{}," (5th ed., text rev.). APA Publishing.",[187,1768,1769,1770,1773],{},"Antshel, K. M., Zhang-James, Y., & Faraone, S. V. (2016). The comorbidity of ADHD and autism spectrum disorder. ",[31,1771,1772],{},"Expert Review of Neurotherapeutics",", 13(10), 1117–1128.",[187,1775,1776,1777,1780,1781],{},"Craddock, N. (2024). \"I Just Thought I Was Weird\": The Experiences of Late-Diagnosed Autistic-ADHD Women. ",[31,1778,1779],{},"Qualitative Health Research",", 34(11), 1065–1076. ",[127,1782,1783],{"href":1783,"rel":1784},"https:\u002F\u002Fdoi.org\u002F10.1177\u002F10497323241253412",[258],[187,1786,1787,1788,1791,1792],{},"Johansson, V., Norén Selinus, E., Salazar Sánchez, V., et al. (2020). Medication prescription patterns for ADHD in individuals with co-occurring autism spectrum disorder. ",[31,1789,1790],{},"Journal of Neurodevelopmental Disorders",", 12(1), 46. ",[127,1793,1794],{"href":1794,"rel":1795},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs11689-020-09352-z",[258],[187,1797,1798,1799,1802],{},"Kessler, R. C., Adler, L., Ames, M., et al. (2005). The World Health Organization Adult ADHD Self-Report Scale (ASRS). ",[31,1800,1801],{},"Psychological Medicine",", 35(2), 245–256.",[187,1804,1805,1806,1809],{},"Leitner, Y. (2014). The co-occurrence of autism and attention deficit hyperactivity disorder in children: what do we know? ",[31,1807,1808],{},"Frontiers in Human Neuroscience",", 8, 268.",[187,1811,1812,1813,1816],{},"Mayes, S. D., Calhoun, S. L., Mayes, R. D., & Molitoris, S. (2012). Autism and ADHD: overlapping and discriminating symptoms. ",[31,1814,1815],{},"Research in Autism Spectrum Disorders",", 6(1), 277–285.",[187,1818,1819,1820,1823,1824],{},"Micai, M., Fatta, L. M., Gila, L., et al. (2023). Prevalence of co-occurring conditions in children and adults with autism spectrum disorder. ",[31,1821,1822],{},"Neuroscience & Biobehavioural Reviews",", 155, 105463. ",[127,1825,1826],{"href":1826,"rel":1827},"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.neubiorev.2023.105463",[258],[187,1829,1830,1831,1834],{},"Ritvo, R. A., Ritvo, E. R., Guthrie, D., et al. (2011). The Ritvo Autism Asperger Diagnostic Scale–Revised (RAADS–R). ",[31,1832,1833],{},"Journal of Autism and Developmental Disorders",", 41(8), 1076–1089.",[187,1836,1837,1838,1841],{},"Rommelse, N. N. J., Franke, B., Geurts, H. M., Hartman, C. A., & Buitelaar, J. K. (2010). Shared heritability of attention-deficit\u002Fhyperactivity disorder and autism spectrum disorder. ",[31,1839,1840],{},"European Child & Adolescent Psychiatry",", 19(3), 281–295.",[187,1843,1844,1845,1848],{},"Shulman, L., D'Agostino, S. L., & Lerner, M. D. (2020). The Role of Diagnostic Instruments in Dual\u002FDifferential ASD Diagnosis Across the Lifespan. ",[31,1846,1847],{},"Child and Adolescent Psychiatric Clinics of North America",", 29(2), 275–298.",[187,1850,1851,1852,1855],{},"Young, S., Hollingdale, J., Absoud, M., et al. (2020). Guidance for identification and treatment of individuals with ADHD and autism spectrum disorder based upon expert consensus. ",[31,1853,1854],{},"BMC Medicine",", 18(1), 146.",{"title":303,"searchDepth":304,"depth":304,"links":1857},[1858,1859,1860,1861,1862,1863,1864,1865],{"id":1500,"depth":307,"text":1501},{"id":1623,"depth":307,"text":1624},{"id":1641,"depth":307,"text":1642},{"id":1659,"depth":307,"text":1660},{"id":1677,"depth":307,"text":1678},{"id":1714,"depth":307,"text":1715},{"id":1196,"depth":307,"text":1197},{"id":815,"depth":307,"text":816},[314],"\u002Fimg\u002Fcontent\u002Finsights\u002Fadhd-vs-autism.webp",{},"\u002Finsights\u002Fadhd-vs-autism","2026-03-09T10:00:00Z",{"title":1476,"description":1481},"adhd-vs-autism","insights\u002Fadhd-vs-autism",[1875,1876,1877,1878,1879,1880,1881],"adhd","autism","audhd","neurodevelopmental","differential-diagnosis","screening","adult mental health","xxQlOzqroZmpKoigW2wtcJ6LDYAgUN7FoJWC9y0f3ko",[]]